Cure My Disease

Don't miss your cure!

 Log in / Sign up

New score could save lives by predicting bleeding deaths in cirrhosis patients

NCT ID NCT04662918

Knowledge-focused Sponsor: Xingshun Qi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is testing a new scoring system called CAGIB to predict the risk of death in the hospital for people with liver cirrhosis who have sudden gastrointestinal bleeding. Researchers will compare CAGIB with two older scoring systems (Child-Pugh and MELD) in 3,000 patients across multiple countries. The goal is to see which score best helps doctors quickly identify the sickest patients so they can act faster.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could give doctors a more accurate tool to predict which patients are at highest risk of dying in the hospital, helping them make faster treatment decisions.
What could go wrong
This is an observational study, not a treatment trial. The new score may not prove better than existing ones, and results may not apply to all patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 3,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2022

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with liver cirrhosis and acute gastrointestinal bleeding

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with liver cirrhosis; 2. Patients with acute gastrointestinal bleeding presenting with hematemesis, melena, and/or hematochezia; 3. Adults (age≥18 years old). Exclusion Criteria: 1. Components of Child-Pugh, MELD, and CAGIB scores are not available; 2. In-hospital outcomes are not evaluable.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastrointestinal bleeding are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Gastrointestinal Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastrointestinal bleeding

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    23 sites in 8 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Air Force Hospital of Northern Theater Command

    RECRUITING

    Shenyang, Liaoning, China

  • Azienda di Rilievo Nazionale ad Alta Specializzazione Civico-Di Cristina-Benfratelli

    RECRUITING

    Palermo, Palermo, Italy

  • Beijing Youan Hospital, Capital Medical University

    RECRUITING

    Beijing, Beijing Municipality, China

  • Bezmialem Vakif University

    RECRUITING

    Istanbul, Istanbul, Turkey (Türkiye)

  • Cathay General Hospital, Fu-Jen Catholic University School of Medicine

    NOT_YET_RECRUITING

    Taibei, Taiwan, China

  • Charité University Medical Center

    RECRUITING

    Berlin, State of Berlin, Germany

  • Ernakulam Medical Center

    NOT_YET_RECRUITING

    Kochi, Kochi, India

  • First Affiliated Hospital of Fujian Medical University

    RECRUITING

    Fuzhou, Fujian, China

  • First Affiliated Hospital of Nanchang University

    RECRUITING

    Nanchang, Jiangxi, China

  • General Hospital of Northern Theater Command

    RECRUITING

    Shenyang, Liaoning, China

  • National Autonomous University of Mexico

    RECRUITING

    Mexico City, Mexico City, Mexico

  • Shandong Provincial Hospital

    RECRUITING

    Jinan, Shandong, China

  • São Paulo State University (UNESP), Botucatu Medical School

    RECRUITING

    São Paulo, São Paulo, Brazil

  • Tangdu Hospital, Fourth Military Medical University,

    RECRUITING

    Xi'an, Shaanxi, China

  • The First Affiliated Hospital of Xi'an Jiao Tong University

    RECRUITING

    Xi'an, Shaanxi, China

  • The First Hospital of China Medical University

    RECRUITING

    Shenyang, Liaoning, China

  • The Second Affiliated Hospital of Xi'an Jiao Tong University

    RECRUITING

    Xi'an, Shaanxi, China

  • The Seventh Medical Center of Chinese PLA General Hospital

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, China

  • The Six People's Hospital of Dalian

    RECRUITING

    Dalian, Liaoning, China

  • The Six People's Hospital of Shenyang

    RECRUITING

    Shenyang, Liaoning, China

  • The Wright Center for Graduate Medical Education, 501 S. Washington Avenue

    NOT_YET_RECRUITING

    Scranton, Pennsylvania, 18503, United States

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, China

  • Xi'an Central Hospital

    RECRUITING

    Xi'an, Shaanxi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.